entertainment -WSS

entertainment

author：knowledge 2025-10-02 00:43:22 - browse：91896

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Sanofi says it has 12 blockbusters on the way. Will investors believe it?

explore

WSS

Spinal cord stimulation reduces pain in amputees, study finds

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

What PEPFAR has meant on the ground in Ukraine

Pfizer plans to depart BIO

The woman behind the Dana Farber

Adam's Biotech Scorecard: Do Sarepta's exon

hotspot

entertainment

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Latest bird flu infection made farmworker sicker than earlier cases

Sports medicine is finally prioritizing gender equality

Pharma patents targeted by Biden in move to slash drug prices

Jerome Adams on the need for new antivirals for Covid

What will save rural psychiatry services? Higher Medicaid payments

After affirmative action ruling, medical educators look to 'holistic review'

AI models in health care face new federal disclosure requirements

Anesthesiologist group: stop taking Ozempic before surgery

Startling documents reveal new facets of Sacklers' opioid empire

focus

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

CMS should re

Prosthetic arm enables patients to feel the objects they grip

Leukemia patients are helped by Syndax's new type of therapy

explore

entertainment

knowledge

entertainment